Critical Pharma announces start of first Phase I study of nano-enabled intranasal teriparatide
UK-based biotechnology firm Critical Pharmaceuticals has announced the start of the first Phase I clinical trial of a nano-enabled intranasal teriparatide product in healthy post-menopausal women for the treatment of osteoporosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Clinical Trials | Forteo | Men | Menopause | Nanotechnology | Orthopaedics | Osteoporosis | Pharmaceuticals | Study | Women